CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report)’s stock price dropped 13.7% during mid-day trading on Tuesday . The company traded as low as $2.77 and last traded at $2.96. Approximately 313,428 shares traded hands during trading, a decline of 89% from the average daily volume of 2,783,089 shares. The stock had previously closed at $3.43.
Analyst Ratings Changes
Separately, Benchmark reiterated a “speculative buy” rating and issued a $5.00 price objective on shares of CytoMed Therapeutics in a report on Thursday, October 10th.
Read Our Latest Analysis on GDTC
CytoMed Therapeutics Stock Down 22.6 %
About CytoMed Therapeutics
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Read More
- Five stocks we like better than CytoMed Therapeutics
- What is a support level?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Technology Stocks Explained: Here’s What to Know About Tech
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Health Care Stocks Explained: Why You Might Want to Invest
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
